Generali Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
Other funds holding ALNY
Generali Asset Management's ALNY Position: Q3 2026 in Review
Generali Asset Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 88% in Q3 2026, selling an estimated $403K and leaving 214 shares worth $52.8K. The position accounts for ﹤0.01% of the portfolio, ranked #467.
Generali Asset Management first reported a position in ALNY in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.47M in Q3 2025. 730 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.
- Generali Asset Management held 214 shares of Alnylam Pharmaceuticals worth $52.8K as of Q3 2026.
- Generali Asset Management sold 1,585 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $403K.
- Alnylam Pharmaceuticals made up ﹤0.01% of Generali Asset Management's portfolio in Q3 2026, its #467 holding.
- Generali Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
- Generali Asset Management's Alnylam Pharmaceuticals position peaked at $1.47M in Q3 2025.
- 730 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.
Based on Generali Asset Management's 13F filing for Q3 2026, filed 26 Oct 2026.